UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2328-3
Program Prior Authorization/Medical Necessity
Medication Voquezna® (vonoprazan)
P&T Approval Date 3/2024, 6/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Voquezna is a potassium-competitive acid blocker indicated for healing and to maintain healing
of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis
and non-erosive gastroesophageal reflux disease in adults, and in combination with amoxicillin
or amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection
in adults.
2. Coverage Criteriaa:
A. Erosive Esophagitis and Non-Erosive Gastroesophageal Reflux Disease (GERD)
1. Authorization
a. Voquezna will be approved based on both of the following:
(1) One of the following:
(a) For the treatment or maintenance of erosive esophagitis
(b) For the treatment of non-erosive gastroesophageal reflux disease (GERD)
-AND-
(2) History of failure, contraindication, or intolerance to one of the following:
(a) omeprazole
(b) pantoprazole
(c) rabeprazole
Authorization will be issued for 9 months.
B. Helicobacter Pylori
1. Authorization
a. Voquezna will be approved based on both of the following:
(1) For the treatment of Helicobacter pylori (H. pylori) in combination with amoxicillin
or amoxicillin and clarithromycin
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) History of failure, contraindication, or intolerance to one of the following:
(a) omeprazole
(b) pantoprazole
(c) rabeprazole
Authorization will be issued for 1 month.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Voquezna [package insert]. Buffalo Grove, IL: Phathom Pharmceuticals Inc.; November 2023.
2. Chey, WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J
Gastroenterol 2017; 112:212–238; doi: 10.1038/ajg.2016.563; published online 10 January 2017.
Program Prior Authorization/Medical Necessity – Voquezna
Change Control
3/2024 New program.
6/2024 Updated step one options to include omeprazole and pantoprazole.
1/2025 Added coverage for GERD based on updated labeling.
© 2025 UnitedHealthcare Services, Inc.
2